Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts


ABSTRACT: The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signaling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P3. Finally, pharmacologic treatment with the non-selective S1P receptor agonist FTY720 causes increased bone formation in wildtype, but not in S1P3-deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo, and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts. Osteoclasts of wildtype and Calcr-/- C57Bl/6 mice were treated with Calcitonin and compared to the non-treated osteoclasts of wildtype or Calcr-/- mice, respectively.

ORGANISM(S): Mus musculus

SUBMITTER: Thomas Streichert 

PROVIDER: E-GEOD-60761 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2014-10-19 | GSE60761 | GEO
2012-08-18 | E-GEOD-37219 | biostudies-arrayexpress
2010-03-22 | E-GEOD-20850 | biostudies-arrayexpress
2015-04-01 | E-GEOD-45656 | biostudies-arrayexpress
2023-01-25 | PXD037006 | Pride
2023-01-25 | PXD037813 | Pride
2021-06-07 | PXD023578 | Pride
2023-01-25 | PXD037910 | Pride
2015-12-31 | E-GEOD-53017 | biostudies-arrayexpress
2015-02-23 | E-GEOD-59387 | biostudies-arrayexpress